公司資料
ProMIS Neurosciences 股價、新聞與催化劑
- 股票代碼:
- PMN
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- Canada and listed in the U
股票表現
14.66 USD (-1.35%)
收盤價
最後更新: 2026年8月17日
91M USD
市值
股價為何變動
As of Aug 17, 2026, PMN closed down 1.35% at $14.66. No new same-company headline was identified in the current news window.
公司概覽
Misfolded Protein Therapeutics
ProMIS Neurosciences develops antibodies that selectively recognize toxic misfolded protein species implicated in neurodegenerative disease.
PMN310
PMN310 targets toxic amyloid-beta oligomers while seeking to avoid binding monomers and plaque, potentially reducing off-target immune effects.
PRECISE-AD
The fully enrolled Phase 1b PRECISE-AD study evaluates PMN310 in patients with Alzheimer’s disease using safety, imaging, and biomarker measures.
未來催化劑
- Twelve-month unblinded topline results from the Phase 1b PRECISE-AD study of PMN310 in the first quarter of 2027.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。